(RVMD) Revolution Medicines - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US76155X1000
Stock:
Total Rating 40
Risk 69
Buy Signal -0.24
| Risk 5d forecast | |
|---|---|
| Volatility | 48.7% |
| Relative Tail Risk | -14.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.92 |
| Alpha | 134.50 |
| Character TTM | |
|---|---|
| Beta | 1.052 |
| Beta Downside | 1.332 |
| Drawdowns 3y | |
|---|---|
| Max DD | 48.63% |
| CAGR/Max DD | 1.22 |
EPS (Earnings per Share)
Revenue
Description: RVMD Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -961.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA -16.62 > 1.0 |
| NWC/Revenue: 682.2% < 20% (prev 291.6k%; Δ -290.9k% < -1%) |
| CFO/TA -0.38 > 3% & CFO -897.7m > Net Income -961.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.14 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (190.1m) vs prev 13.35% < -2% |
| Gross Margin: -52.01% > 18% (prev -563.9%; Δ 51.2k% > 0.5%) |
| Asset Turnover: 10.65% > 50% (prev 0.03%; Δ 10.62% > 0%) |
| Interest Coverage Ratio: -82.39 > 6 (EBITDA TTM -1.00b / Interest Expense TTM 12.3m) |
Altman Z'' -5.94
| A: 0.76 (Total Current Assets 2.08b - Total Current Liabilities 290.4m) / Total Assets 2.35b |
| B: -1.22 (Retained Earnings -2.87b / Total Assets 2.35b) |
| C: -0.41 (EBIT TTM -1.02b / Avg Total Assets 2.46b) |
| D: -3.96 (Book Value of Equity -2.87b / Total Liabilities 723.2m) |
| Altman-Z'' Score: -5.94 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 261.6m/742.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.40 (AQ_t 0.05 / AQ_t-1 0.03) |
| SGI: 352.5 (Revenue 261.6m / 742.0k) |
| TATA: -0.03 (NI -961.0m - CFO -897.7m) / TA 2.35b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of RVMD shares?
As of February 28, 2026, the stock is trading at USD 102.02 with a total of 7,143,862 shares traded.
Over the past week, the price has changed by +0.19%, over one month by +2.20%, over three months by +31.20% and over the past year by +161.05%.
Over the past week, the price has changed by +0.19%, over one month by +2.20%, over three months by +31.20% and over the past year by +161.05%.
Is RVMD a buy, sell or hold?
Revolution Medicines has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy RVMD.
- StrongBuy: 8
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RVMD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 122.7 | 20.3% |
| Analysts Target Price | 122.7 | 20.3% |
RVMD Fundamental Data Overview February 27, 2026
P/S = 9035.0954
P/B = 4.5797
Revenue TTM = 261.6m USD
EBIT TTM = -1.02b USD
EBITDA TTM = -1.00b USD
Long Term Debt = 142.2m USD (estimated: total debt 158.7m - short term 16.5m)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 158.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -225.0m USD (from netDebt column, last quarter)
Enterprise Value = 18.09b USD (19.96b + Debt 158.7m - CCE 2.03b)
Interest Coverage Ratio = -82.39 (Ebit TTM -1.02b / Interest Expense TTM 12.3m)
EV/FCF = -19.80x (Enterprise Value 18.09b / FCF TTM -913.7m)
FCF Yield = -5.05% (FCF TTM -913.7m / Enterprise Value 18.09b)
FCF Margin = -349.3% (FCF TTM -913.7m / Revenue TTM 261.6m)
Net Margin = -367.4% (Net Income TTM -961.0m / Revenue TTM 261.6m)
Gross Margin = -52.01% ((Revenue TTM 261.6m - Cost of Revenue TTM 397.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.68 (Enterprise Value 18.09b / Total Assets 2.35b)
Interest Expense / Debt = 7.20% (Interest Expense 11.4m / Debt 158.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -802.3m (EBIT -1.02b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.14 (Total Current Assets 2.08b / Total Current Liabilities 290.4m)
Debt / Equity = 0.10 (Debt 158.7m / totalStockholderEquity, last quarter 1.63b)
Debt / EBITDA = 0.22 (negative EBITDA) (Net Debt -225.0m / EBITDA -1.00b)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -225.0m / FCF TTM -913.7m)
Total Stockholder Equity = 1.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -39.12% (Net Income -961.0m / Total Assets 2.35b)
RoE = -53.60% (Net Income TTM -961.0m / Total Stockholder Equity 1.79b)
RoCE = -52.48% (EBIT -1.02b / Capital Employed (Equity 1.79b + L.T.Debt 142.2m))
RoIC = -43.44% (negative operating profit) (NOPAT -802.3m / Invested Capital 1.85b)
WACC = 9.76% (E(19.96b)/V(20.12b) * Re(9.79%) + D(158.7m)/V(20.12b) * Rd(7.20%) * (1-Tc(0.21)))
Discount Rate = 9.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.77%
[DCF] Fair Price = unknown (Cash Flow -913.7m)
EPS Correlation: -79.09 | EPS CAGR: -49.13% | SUE: -2.05 | # QB: 0
Revenue Correlation: -40.37 | Revenue CAGR: -73.41% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.64 | Chg7d=+0.007 | Chg30d=+0.006 | Revisions Net=-2 | Analysts=9
EPS next Year (2026-12-31): EPS=-6.61 | Chg7d=-0.079 | Chg30d=-0.081 | Revisions Net=-5 | Growth EPS=-19.4% | Growth Revenue=+870.7%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
P/B = 4.5797
Revenue TTM = 261.6m USD
EBIT TTM = -1.02b USD
EBITDA TTM = -1.00b USD
Long Term Debt = 142.2m USD (estimated: total debt 158.7m - short term 16.5m)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 158.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -225.0m USD (from netDebt column, last quarter)
Enterprise Value = 18.09b USD (19.96b + Debt 158.7m - CCE 2.03b)
Interest Coverage Ratio = -82.39 (Ebit TTM -1.02b / Interest Expense TTM 12.3m)
EV/FCF = -19.80x (Enterprise Value 18.09b / FCF TTM -913.7m)
FCF Yield = -5.05% (FCF TTM -913.7m / Enterprise Value 18.09b)
FCF Margin = -349.3% (FCF TTM -913.7m / Revenue TTM 261.6m)
Net Margin = -367.4% (Net Income TTM -961.0m / Revenue TTM 261.6m)
Gross Margin = -52.01% ((Revenue TTM 261.6m - Cost of Revenue TTM 397.6m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 7.68 (Enterprise Value 18.09b / Total Assets 2.35b)
Interest Expense / Debt = 7.20% (Interest Expense 11.4m / Debt 158.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -802.3m (EBIT -1.02b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.14 (Total Current Assets 2.08b / Total Current Liabilities 290.4m)
Debt / Equity = 0.10 (Debt 158.7m / totalStockholderEquity, last quarter 1.63b)
Debt / EBITDA = 0.22 (negative EBITDA) (Net Debt -225.0m / EBITDA -1.00b)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -225.0m / FCF TTM -913.7m)
Total Stockholder Equity = 1.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -39.12% (Net Income -961.0m / Total Assets 2.35b)
RoE = -53.60% (Net Income TTM -961.0m / Total Stockholder Equity 1.79b)
RoCE = -52.48% (EBIT -1.02b / Capital Employed (Equity 1.79b + L.T.Debt 142.2m))
RoIC = -43.44% (negative operating profit) (NOPAT -802.3m / Invested Capital 1.85b)
WACC = 9.76% (E(19.96b)/V(20.12b) * Re(9.79%) + D(158.7m)/V(20.12b) * Rd(7.20%) * (1-Tc(0.21)))
Discount Rate = 9.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.77%
[DCF] Fair Price = unknown (Cash Flow -913.7m)
EPS Correlation: -79.09 | EPS CAGR: -49.13% | SUE: -2.05 | # QB: 0
Revenue Correlation: -40.37 | Revenue CAGR: -73.41% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.64 | Chg7d=+0.007 | Chg30d=+0.006 | Revisions Net=-2 | Analysts=9
EPS next Year (2026-12-31): EPS=-6.61 | Chg7d=-0.079 | Chg30d=-0.081 | Revisions Net=-5 | Growth EPS=-19.4% | Growth Revenue=+870.7%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)